Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.
It has an incubation period of 14-180 days.
Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.
Use of direct-acting antivirals to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.
Diabetic patients with hepatitis C virus (HCV) may benefit from direct-acting antiviral agents, with a significant portion of patients having a clinically significant reduction in glycated haemoglobin (HbA1c), suggests a recent study. This effect has been sustained among responders over 1.5 years of follow-up.
Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress™ (ILC 2019) showed.
The use of glecaprevir plus pibrentasvir appears to be safe and highly effective in the treatment of chronic hepatitis C virus (HCV) infection genotypes 1–3 in patients with severe renal impairment, including those undergoing haemodialysis, as shown in a recent study from Japan.
Combination treatment with glecaprevir plus pibrentasvirproduces a sustained virological response in more than 90 percent of hepatitis C virus (HCV)-infected patients who previously failed direct-acting antiviral (DAA) treatments, regardless of liver fibrosis stage, a study has shown.
Patients with chronic hepatitis C virus (HCV) infection who are treated with direct-acting antivirals (DAAs) have a reduced risk of all-cause mortality and hepatocellular carcinoma (HCC), according to results of an observational French study.
Achieving sustained virological response in hepatitis C virus (HCV)-infected patients with type 2 diabetes (T2D) substantially cuts the risk of developing acute coronary syndrome, end‐stage renal disease, ischaemic stroke and retinopathy, regardless of cirrhosis, a study has shown.
Antiviral treatment with pegylated interferon and ribavirin leads to a significant reduction in the risk of lymphoma, especially the non-Hodgkin’s type, in patients with chronic hepatitis C virus (HCV) infection, according to a study.
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Acne is a common skin problem seen in primary care. Dr Wong
Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore
shares his insights with Pearl Toh on how to manage acne in the primary care